DongKoo Bio & Pharma Past Earnings Performance
Past criteria checks 2/6
DongKoo Bio & Pharma has been growing earnings at an average annual rate of 0.5%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 15.3% per year. DongKoo Bio & Pharma's return on equity is 10.7%, and it has net margins of 5.5%.
Key information
0.5%
Earnings growth rate
1.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 15.3% |
| Return on equity | 10.7% |
| Net Margin | 5.5% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How DongKoo Bio & Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 215,686 | 11,812 | 105,621 | 10,752 |
| 30 Sep 23 | 201,715 | 6,822 | 100,571 | 9,220 |
| 30 Jun 23 | 199,507 | 8,685 | 97,791 | 8,361 |
| 31 Mar 23 | 196,174 | 6,251 | 94,387 | 8,326 |
| 31 Dec 22 | 194,988 | 6,614 | 91,638 | 8,258 |
| 30 Sep 22 | 187,109 | 8,401 | 87,157 | 8,263 |
| 30 Jun 22 | 176,858 | 7,641 | 81,802 | 9,131 |
| 31 Mar 22 | 166,045 | 11,365 | 77,511 | 9,702 |
| 31 Dec 21 | 155,149 | 9,327 | 73,093 | 10,114 |
| 30 Sep 21 | 149,031 | 7,455 | 70,368 | 10,698 |
| 30 Jun 21 | 144,081 | 7,349 | 67,426 | 11,526 |
| 31 Dec 20 | 139,216 | 9,140 | 61,386 | 10,751 |
| 31 Dec 17 | 101,124 | 10,943 | 43,323 | 3,681 |
| 30 Sep 17 | 100,468 | 15,877 | 41,527 | 2,989 |
| 30 Jun 17 | 95,942 | 13,618 | 40,364 | 2,727 |
| 31 Dec 16 | 87,363 | 10,913 | 39,383 | 2,111 |
| 31 Dec 15 | 80,369 | 4,030 | 38,410 | 2,819 |
Quality Earnings: A006620 has a high level of non-cash earnings.
Growing Profit Margin: A006620's current net profit margins (5.5%) are higher than last year (3.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A006620's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A006620's past year earnings growth to its 5-year average.
Earnings vs Industry: A006620 earnings growth over the past year (78.6%) exceeded the Pharmaceuticals industry 36.1%.
Return on Equity
High ROE: A006620's Return on Equity (10.7%) is considered low.